I2Pure Hired Three Leaders to Scale Operations
The company added leadership and scientific talent to support manufacturing growth and R&D for its iodine platform.
Updated on Oct. 5, 2026 in People
I2Pure has added three new staff members to its team, including a new Vice President of Production and Supply Chain. These hires aim to bolster the company's manufacturing capacity and research support for its molecular iodine technology.
Why it matters
The company is scaling its manufacturing and research divisions, a shift often necessary for firms moving from development to commercial operations. Expanding teams in specialized technical roles is a common indicator of a firm preparing for increased output or market entry.
The company added three new specialized staff members, including a Vice President managing a business unit previously valued at over $350 million in global GMP assets. The move brings over 45 years of combined experience in quality, regulatory, and production leadership to the firm.
The players
I2Pure
A life sciences company focused on developing and commercializing molecular iodine technology platforms.
Christopher Wilkes
The incoming Vice President of Production and Supply Chain who previously managed $350+ million in GMP business value.
Nichole Coggins
The new Director of Quality Engineering, bringing over 20 years of experience in regulatory and quality leadership.
Maggie Engert
A newly appointed Biomaterials Scientist specializing in biodefense and public health research.
The details
Christopher Wilkes and Nichole Coggins join the Asheville, North Carolina manufacturing facility to oversee supply chain operations and quality engineering. Simultaneously, Maggie Engert will support the research and development pipeline at the company's lab in Manassas, Virginia. These roles are structured to handle the technical complexities of scaling molecular iodine products while maintaining compliance standards.
Timeline
October 5, 2026: I2Pure announced the three personnel hires.
Market Landscape
This talent acquisition follows the typical scaling phase of a life sciences startup as it moves toward high-volume production. The move reflects an industry-wide trend of securing heavy-duty GMP compliance expertise to bridge the gap between bench-scale R&D and commercial manufacturing.
Operators in the biotech and manufacturing space should monitor how new quality leadership impacts supply chain lead times. Assess whether your current production scaling is supported by staff with similar experience in managing high-value GMP business units.
The takeaway
Technical scaling requires a clear division between production operations and R&D oversight. Monitor the development of the molecular iodine platform as an industry signal for effective technology commercialization.
Further reading
For more on industry hiring trends and leadership shifts, visit our People section.
More information
View the detailed staff expansion biographies for more information on the incoming leadership team.
